Gilead awarded massive damages in fraud case

10 March 2023

US biotech Gilead Sciences (Nasdaq: GILD) has now been awarded damages totalling nearly a quarter of a billion dollars in a case that the drugmaker filed against several healthcare clinics, pharmacies, prescribers, and lab testing facilities.

Gilead had accused the companies of an alleged scheme to steal millions of dollars from its Medication Assistance Program (MAP), which provides eligible uninsured persons with free medication to help protect them from becoming infected with HIV.

In November 2020, Gilead filed a lawsuit alleging that the defendants participated in the fraud scheme, including fraudulently enrolling patients in MAP, purchasing already-dispensed medication back from enrollees so it could be resold, performing sham wellness checks on patients and using their credentials to improperly write prescriptions, and submitting fraudulent redemptions, among other tactics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK